Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.50 |
| ▸ | ITGAV | P06756 | 10/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 3/20 | 0.45 |
| ▸ | MC5R | P33032 | 3/20 | 0.45 |
| ▸ | MC3R | P41968 | 3/20 | 0.45 |
| ▸ | MC1R | Q01726 | 3/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13446003 | 0.99 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5KEAP1 | |
| SCHEMBL13445984 | 0.92 | KEAP1 (0.51) | ITGB3ITGAVITGB1ITGA5KEAP1 | |
| SCHEMBL13445988 | 0.88 | KEAP1 (0.42) | ITGB3ITGAVITGB1ITGA5KEAP1 | |
| SCHEMBL13481626 | 0.84 | ITGB3 (0.59) | ITGB3ITGAVITGB1ITGA5KEAP1 | |
| SCHEMBL8205616 | 0.84 | ITGB3 (0.59) | ITGB3ITGAVITGB1ITGA5KEAP1 | |
| SCHEMBL13299963 | 0.83 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL21186264 | 0.83 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL21907003 | 0.83 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL21906964 | 0.83 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R | |
| SCHEMBL16359838 | 0.83 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293206-B2 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | MKI67, CD47, CD68 | ITGB3 251/4885ITGAV 204/4885ITGB1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.